RE: Evaluation of Keytruda and CAR T-cell therapy for cancer treatment: The similarities and differences therein
Thanks a lot for the mention and coming back to the point I raised in your previous blog. This clarifies a lot what Keytruda is and how different it is from a CAR T-cell-based treatment.
I have a couple of very naive comments/questions. The trickiest cancer cells are those traveling freely in our body. Is that correct that they could avoid both CAR T-cell and Keytruda treatment? Or can both treatment work on any cancer cell in our body, anywhere it is. Moreover, could a joint use of CAR T-cell and Keytruda be helpful here, as they target slightly different proteins (PD-1/CD19 if I have well understood). I have the impression that such a joint usage is not necessary as both treatment works quite nicely alone.
Finally, as a last question, is it also correct to say that Keytruda is an easier treatment to take, as we don’t need to deal with chimeric gene insertion into T lymphocytes?
Thanks in advance for your answers!